Загрузка...
Beyond chemotherapy - emerging biomarkers and therapies as SCLC enters the immune checkpoint era
For decades, clinicians have seen no therapeutic advances for SCLC, including no FDA-approved targeted therapies; recently, immune checkpoint blockade has emerged as a promising new option for the treatment of relapsed SCLC (including recent FDA approval of nivolumab in the third-line setting) and m...
Сохранить в:
| Опубликовано в: : | Cancer |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6353664/ https://ncbi.nlm.nih.gov/pubmed/30620399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31863 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|